FR22C1014I2 - Anticorps contre le facteur de croissance neuronale et leurs procédés de préparation et d'utilisation - Google Patents

Anticorps contre le facteur de croissance neuronale et leurs procédés de préparation et d'utilisation

Info

Publication number
FR22C1014I2
FR22C1014I2 FR22C1014C FR22C1014C FR22C1014I2 FR 22C1014 I2 FR22C1014 I2 FR 22C1014I2 FR 22C1014 C FR22C1014 C FR 22C1014C FR 22C1014 C FR22C1014 C FR 22C1014C FR 22C1014 I2 FR22C1014 I2 FR 22C1014I2
Authority
FR
France
Prior art keywords
preparing
methods
growth factor
neuronal growth
factor antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1014C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12723731.1A external-priority patent/EP2705055B1/en
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of FR22C1014I1 publication Critical patent/FR22C1014I1/fr
Application granted granted Critical
Publication of FR22C1014I2 publication Critical patent/FR22C1014I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR22C1014C 2011-05-06 2022-04-08 Anticorps contre le facteur de croissance neuronale et leurs procédés de préparation et d'utilisation Active FR22C1014I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161483488P 2011-05-06 2011-05-06
US201161531439P 2011-09-06 2011-09-06
EP12723731.1A EP2705055B1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same
PCT/GB2012/051003 WO2012153122A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
FR22C1014I1 FR22C1014I1 (fr) 2022-06-17
FR22C1014I2 true FR22C1014I2 (fr) 2023-01-13

Family

ID=79283336

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1014C Active FR22C1014I2 (fr) 2011-05-06 2022-04-08 Anticorps contre le facteur de croissance neuronale et leurs procédés de préparation et d'utilisation

Country Status (15)

Country Link
EP (1) EP4026845A1 (enrdf_load_stackoverflow)
CY (1) CY1124960T1 (enrdf_load_stackoverflow)
DK (1) DK3498732T3 (enrdf_load_stackoverflow)
ES (1) ES2905682T3 (enrdf_load_stackoverflow)
FI (1) FIC20220010I1 (enrdf_load_stackoverflow)
FR (1) FR22C1014I2 (enrdf_load_stackoverflow)
HR (1) HRP20211869T1 (enrdf_load_stackoverflow)
HU (2) HUE057288T2 (enrdf_load_stackoverflow)
LT (2) LT3498732T (enrdf_load_stackoverflow)
LU (1) LUC00254I2 (enrdf_load_stackoverflow)
NL (1) NL301168I2 (enrdf_load_stackoverflow)
NO (1) NO2022008I1 (enrdf_load_stackoverflow)
PL (1) PL3498732T3 (enrdf_load_stackoverflow)
PT (1) PT3498732T (enrdf_load_stackoverflow)
SI (1) SI3498732T1 (enrdf_load_stackoverflow)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2005514063A (ja) * 2001-12-21 2005-05-19 イデックス ラボラトリーズ インコーポレイテッド イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
ES2665954T3 (es) * 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso

Also Published As

Publication number Publication date
PL3498732T3 (pl) 2022-02-28
DK3498732T3 (da) 2022-01-17
NO2022008I1 (no) 2022-04-04
NL301168I2 (nl) 2022-11-24
LTPA2022005I1 (enrdf_load_stackoverflow) 2022-04-25
CY1124960T1 (el) 2023-01-05
EP4026845A1 (en) 2022-07-13
NL301168I1 (enrdf_load_stackoverflow) 2022-04-13
SI3498732T1 (sl) 2022-04-29
PT3498732T (pt) 2022-02-02
FR22C1014I1 (fr) 2022-06-17
ES2905682T3 (es) 2022-04-11
LUC00254I2 (enrdf_load_stackoverflow) 2025-03-04
HUS2200012I1 (hu) 2022-05-28
HUE057288T2 (hu) 2022-04-28
LT3498732T (lt) 2022-01-10
FIC20220010I1 (fi) 2022-04-04
HRP20211869T1 (hr) 2022-03-04

Similar Documents

Publication Publication Date Title
EP2702078A4 (en) Anti-cd40 antibodies and methods of use
EP2766393A4 (en) ANTI-HTRA1 ANTIBODIES AND USE METHOD
EP2663579A4 (en) THERAPEUTIC ANTIBODIES AGAINST THE PROTEIN ROR-1 AND METHOD FOR THEIR USE
EP2748199A4 (en) ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP2552959A4 (en) ANTIBODY AGAINST MUC16 AND METHOD OF USE THEREOF
EP2709647A4 (en) WATER-SOLUBLE MEMBRANE PROTEINS AND METHOD FOR THEIR PREPARATION AND USE
EP2539473A4 (en) MODIFIED PROTEINS AND METHOD FOR THEIR PREPARATION AND USE
EP2609118A4 (en) Anti-ox40 antibodies and methods of using the same
EP2704667A4 (en) IMPLANTABLE ENDOLUMINAL SURFACES AND MANUFACTURING METHOD THEREFOR
EP2763541C0 (en) Pest control formulations and methods of making and using same
EP2852404A4 (en) ANTI-LY6E ANTIBODIES AND IMMUNOCONJUGATES AND METHOD OF USE
EP2611832A4 (en) ANTI-CXCL13 ANTIBODIES AND METHOD FOR THEIR USE
EP2723763A4 (en) IMMOBILIZED TRANSAMINASES AND METHOD FOR THE PRODUCTION AND USE OF IMMOBILIZED TRANSAMINASES
EP2771029A4 (en) ANTIBODY FORMULATIONS AND METHOD THEREFOR
EP2651415A4 (en) STOMACH / DARM FORMULATIONS AND METHOD FOR THEIR MANUFACTURE AND USE
EP2831100A4 (en) NUTRIENT PROTEINS AND METHOD
EP2847223A4 (en) ANTI-B7-H6 ANTIBODIES, FUSION PROTEINS AND METHODS OF USE THEREOF
EP2773287A4 (en) PERSONALIZED PROSTHESIS AND USE METHOD THEREFOR
EP2914633A4 (en) ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE
EP2788370A4 (en) MODIFIED MINIHEPCIDINPEPTIDES AND METHOD FOR THEIR USE
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHOD FOR USE THEREOF
EP2718241A4 (en) SYNTHETIC FORMULATIONS AND METHOD FOR THEIR MANUFACTURE AND USE
EP2614084A4 (en) HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE
EP2732025A4 (en) ALGAE LIPID COMPOSITIONS AND METHOD FOR THEIR PRODUCTION AND USE